LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Laboratory diagnosis of SARS-CoV-2: available approaches and limitations.

    Abduljalil, J M

    New microbes and new infections

    2020  Volume 36, Page(s) 100713

    Abstract: ... situation by the US FDA for the diagnosis of SARS-CoV-2. The majority of recently authorized ... The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one ... other molecular approaches were developed and tested. Other recently developed point-of-care molecular tests are ...

    Abstract The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the most devastating outbreaks witnessed in the last 100 years. The outbreak started in China and spread rapidly to almost every country, culminating in woefully overwhelmed health-care systems in most countries. The only approved diagnostic test to accompany radiographic evaluation is reverse transcription PCR. However, the applicability of this test in diagnosis and surveillance is challenged by a global shortage of reagents and the lack of well-equipped laboratories with specialized staff in several low- and middle-income countries. Loop-mediated isothermal amplification and CRISPR-based diagnostic assays have developed and expected to play a role however, their accuracy is still inferior to the recommended PCR approach. The need for the development of accurate and rapid diagnostic assays became apparent. Immunodiagnostic tests and other molecular approaches were developed and tested. Other recently developed point-of-care molecular tests are expected to be helpful in pandemic management as no particular skills are required from the operator. Fortunately, a number of serological tests have been granted authorization for use under the emergency situation by the US FDA for the diagnosis of SARS-CoV-2. The majority of recently authorized serological tests detect IgG and IgM in blood of infected individuals by on ELISA, chemiluminescence platforms or lateral flow cassettes.
    Keywords covid19
    Language English
    Publishing date 2020-06-14
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2750179-6
    ISSN 2052-2975
    ISSN 2052-2975
    DOI 10.1016/j.nmni.2020.100713
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Laboratory diagnosis of SARS-CoV-2: available approaches and limitations

    Abduljalil, J. M.

    New Microbes New Infect.

    Abstract: ... situation by the US FDA for the diagnosis of SARS-CoV-2. The majority of recently authorized ... The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one ... other molecular approaches were developed and tested. Other recently developed point-of-care molecular tests are ...

    Abstract The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the most devastating outbreaks witnessed in the last 100 years. The outbreak started in China and spread rapidly to almost every country, culminating in woefully overwhelmed health-care systems in most countries. The only approved diagnostic test to accompany radiographic evaluation is reverse transcription PCR. However, the applicability of this test in diagnosis and surveillance is challenged by a global shortage of reagents and the lack of well-equipped laboratories with specialized staff in several low- and middle-income countries. Loop-mediated isothermal amplification and CRISPR-based diagnostic assays have developed and expected to play a role however, their accuracy is still inferior to the recommended PCR approach. The need for the development of accurate and rapid diagnostic assays became apparent. Immunodiagnostic tests and other molecular approaches were developed and tested. Other recently developed point-of-care molecular tests are expected to be helpful in pandemic management as no particular skills are required from the operator. Fortunately, a number of serological tests have been granted authorization for use under the emergency situation by the US FDA for the diagnosis of SARS-CoV-2. The majority of recently authorized serological tests detect IgG and IgM in blood of infected individuals by on ELISA, chemiluminescence platforms or lateral flow cassettes.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #597261
    Database COVID19

    Kategorien

  3. Article ; Online: Laboratory diagnosis of SARS-CoV-2

    Abduljalil, J.M.

    New Microbes and New Infections

    available approaches and limitations

    2020  Volume 36, Page(s) 100713

    Keywords covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2750179-6
    ISSN 2052-2975
    ISSN 2052-2975
    DOI 10.1016/j.nmni.2020.100713
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Laboratory diagnosis of SARS-CoV-2

    J.M. Abduljalil

    New Microbes and New Infections, Vol 36, Iss , Pp 100713- (2020)

    available approaches and limitations

    2020  

    Abstract: ... situation by the US FDA for the diagnosis of SARS-CoV-2. The majority of recently authorized ... The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one ... other molecular approaches were developed and tested. Other recently developed point-of-care molecular tests are ...

    Abstract The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the most devastating outbreaks witnessed in the last 100 years. The outbreak started in China and spread rapidly to almost every country, culminating in woefully overwhelmed health-care systems in most countries. The only approved diagnostic test to accompany radiographic evaluation is reverse transcription PCR. However, the applicability of this test in diagnosis and surveillance is challenged by a global shortage of reagents and the lack of well-equipped laboratories with specialized staff in several low- and middle-income countries. Loop-mediated isothermal amplification and CRISPR-based diagnostic assays have developed and expected to play a role however, their accuracy is still inferior to the recommended PCR approach. The need for the development of accurate and rapid diagnostic assays became apparent. Immunodiagnostic tests and other molecular approaches were developed and tested. Other recently developed point-of-care molecular tests are expected to be helpful in pandemic management as no particular skills are required from the operator. Fortunately, a number of serological tests have been granted authorization for use under the emergency situation by the US FDA for the diagnosis of SARS-CoV-2. The majority of recently authorized serological tests detect IgG and IgM in blood of infected individuals by on ELISA, chemiluminescence platforms or lateral flow cassettes.
    Keywords Antigen ; Coronavirus disease 2019 ; Isothermal amplification ; Nasopharyngeal swab ; Real-time RT-PCR ; Serology ; Infectious and parasitic diseases ; RC109-216 ; covid19
    Language English
    Publishing date 2020-07-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top